Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma

Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA
Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma ( Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA )
24 Apr 2024

Do patients and doctors treatment aspirations align? KCCure survey – part A

Prof Michael Staehler and Dena Battle
Do patients and doctors treatment aspirations align? KCCure survey – part A ( Prof Michael Staehler and Dena Battle )
23 Apr 2024

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy

Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA
Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy ( Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA )
12 Apr 2024

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype

Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA
Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype ( Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA )
12 Apr 2024

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio
EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )
9 Apr 2024

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC

Dr Yan Zhang - Sichuan University, Chengdu, China
Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC ( Dr Yan Zhang - Sichuan University, Chengdu, China )
6 Apr 2024

Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer

Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK
Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer ( Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK )
25 Mar 2024

Twice-daily chemoradiation remains the standard of care in limited stage small-cell lung cancer

Dr Gerard Walls - Queen's University Belfast, Belfast, Northern Ireland
Twice-daily chemoradiation remains the standard of care in limited stage small-cell lung cancer ( Dr Gerard Walls - Queen's University Belfast, Belfast, Northern Ireland )
25 Mar 2024

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024

Optimising multiple myeloma care in Latin America

Dr David Gómez-Almaguer - Autonomous University of Nuevo León, Monterrey, Mexico
Optimising multiple myeloma care in Latin America ( Dr David Gómez-Almaguer - Autonomous University of Nuevo León, Monterrey, Mexico )
6 Mar 2024

Global trends and inequalities in breast cancer survival and care

Prof Claudia Allemani, Dr Ophira Ginsburg, Prof Vesna Zadnik
Global trends and inequalities in breast cancer survival and care ( Prof Claudia Allemani, Dr Ophira Ginsburg, Prof Vesna Zadnik )
22 Feb 2024

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda
Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )
22 Feb 2024